ChartMill · Sep 30, 2026
Eton Pharmaceuticals (NASDAQ:ETON): High Growth Momentum Meets a Breakout Setup
ETON pairs high growth momentum with strong technicals and a tradable setup, scoring 10 on trend health and 7 on growth.
ET
NASDAQ · ETON
Eton Pharmaceuticals, Inc.
Healthcare · Biotechnology
$54.88
Up+$0.11 (+0.20%)
Updated Oct 8, 2026, 5:44 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 453.48M
- P/E ratio
- -68.06
- Dividend yield
- 0.00%
- 52-week range
- $16.14 – $66.37
- Volume
- 774.67K
- Avg. volume
- 309.26K
Price performance · ETON
ETON price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
ETON closed at $54.88 after 21 trading sessions, down 6.71% for the selected period.
- Last close
- $54.88
- Period change
- -6.71%
- Period low
- $51.49
- Period high
- $59.49
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $53.84 | $56.42 | $53.55 | $54.88 | 774.67K |
| Oct 6, 2026 | $56.15 | $56.15 | $54.11 | $54.77 | 492.35K |
| Oct 5, 2026 | $55.85 | $56.86 | $54.50 | $55.62 | 405.46K |
| Oct 2, 2026 | $52.42 | $56.00 | $52.00 | $55.36 | 750.08K |
| Oct 1, 2026 | $50.18 | $54.00 | $49.67 | $51.98 | 1.33M |
| Sep 30, 2026 | $59.61 | $59.66 | $48.7901 | $51.49 | 1.81M |
| Sep 29, 2026 | $58.875 | $59.7299 | $57.90 | $59.19 | 710.72K |
| Sep 28, 2026 | $57.68 | $59.7154 | $56.01 | $59.18 | 390.73K |
| Sep 25, 2026 | $60.00 | $60.60 | $57.225 | $57.68 | 514.4K |
| Sep 24, 2026 | $56.19 | $59.62 | $55.34 | $59.49 | 725.85K |
| Sep 23, 2026 | $56.96 | $56.97 | $54.24 | $55.61 | 436.09K |
| Sep 22, 2026 | $55.31 | $57.50 | $55.01 | $57.09 | 484.06K |
| Sep 21, 2026 | $55.50 | $56.745 | $53.60 | $55.31 | 335.51K |
| Sep 18, 2026 | $56.97 | $57.495 | $55.41 | $55.50 | 891.7K |
| Sep 17, 2026 | $57.04 | $58.00 | $55.90 | $57.07 | 314.16K |
| Sep 16, 2026 | $54.76 | $56.84 | $54.75 | $56.35 | 336.21K |
| Sep 15, 2026 | $57.30 | $57.44 | $54.13 | $54.93 | 543.87K |
| Sep 14, 2026 | $58.29 | $58.97 | $57.32 | $57.62 | 352.2K |
| Sep 11, 2026 | $58.99 | $59.98 | $56.445 | $57.08 | 323.59K |
| Sep 10, 2026 | $58.78 | $59.5518 | $57.6107 | $57.88 | 281.7K |
| Sep 9, 2026 | $58.91 | $60.43 | $58.66 | $58.83 | 373.71K |
Latest ETON news
The latest Smart Investors Daily articles mentioning ETON.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ETON research
Overview
Company profile and research snapshot.
Company profile
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $25.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 14, 2026 | B. Riley Securities | Buy | — |
| Aug 14, 2026 | Canaccord Genuity | Buy | — |
| Aug 11, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 28, 2026 | Craig-Hallum | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 28, 2026
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
Eton Pharmaceuticals now holds exclusive commercialization rights for IMPAVIDO in the United StatesEton has integrated full Eton Cares® patient support, including $0 co-pay for eligible commercially insured patients and expanded patient assistance programsCentralized distribution through Anovo Specialty Pharmacy is designed to simplify access and therapy initiation for outpatient prescribing, inpatient consignment, and urgent access coordination DEER PARK, Ill., Sept. 28, 2026 (GLOBE NEWSWIRE) -
Benzinga · Sep 25, 2026
Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach
B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.
Benzinga · Sep 1, 2026
PAUL MAIER V At Eton Pharmaceuticals Executes Options Exercise, Realizing $2.84M
A substantial insider activity was disclosed on August 31, as V, Board Member at Eton Pharmaceuticals (NASDAQ:ETON), reported the exercise of a large sell of company stock options. What Happened: A Form 4 filing with
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
